UBE3A

Recent articles

A hand holds a stack of speech bubbles.

Leveraging the power of community to strengthen clinical trials for rare genetic syndromes

Families can become not only participants but champions of these research efforts.

By Shafali Spurling Jeste
11 July 2024 | 7 min read
Research image of presynapses on sensory neurons in fruit flies.

UBE3A’s link to synaptic pruning bolstered by fly study

Increasing or reducing the levels of the UBE3A gene, which is associated with autism and autism-related syndromes, results in altered patterns of synaptic pruning — a process that snips away brain cell connections.

By Giorgia Guglielmi
28 September 2023 | 5 min read
Research image of interneurons in the outer layer of a human brain.

‘Gain-of-function’ mutation spawns autism traits

The mutation increases the activity of an autism-linked protein and leads to social difficulties and other behavioral differences in mice.

By Giorgia Guglielmi
24 July 2023 | 5 min read
Long-tailed macaque in the canopy of a fruiting strangler fig tree, surrounded by ripening figs. Gunung Palung National Park, Borneo.

RNA therapy restores gene function in monkeys modeling Angelman syndrome

The result raises hopes for an ongoing clinical trial in people — and offers fresh insight into the biology of imprinting and the UBE3A antisense transcript.

By Brendan Borrell
7 April 2023 | 5 min read

Adult Angelman mice get some benefit from boosting UBE3A gene expression

The treatment eases the animals’ sleep troubles, suggesting it has clinically meaningful effects beyond what was thought to be a critical window in early life.

By Angie Voyles Askham
9 February 2023 | 5 min read
Jill Silverman sits at her desk with her dog.

Beyond the bench: Finding solitude with Jill Silverman

The people-focused researcher shares her secrets to carving out time for grant writing, creating work-life balance and letting go of unread emails.

By Peter Hess
17 January 2023 | 7 min read

Promising preclinical results prompt Angelman therapy trial

Roche’s gene therapy drug Rugonersen boosts expression of the protein missing in the syndrome in mice and monkeys, but whether it works in people remains to be seen.

By Angie Voyles Askham
25 August 2022 | 6 min read
An Ultragenyx employee removes materials from a lab freezer.

Angelman therapy appears safer in restarted trial

Interim results from the previously paused trial suggest that doses of the experimental gene therapy drug GTX-102 are well tolerated in children with the autism-linked condition.

By Angie Voyles Askham
5 August 2022 | 4 min read

Enrichment lessens Angelman-like traits in male mice

Model animals don’t develop the usual behavioral and motor problems when reared in an enclosure containing exercise wheels, toys and treats.

By Peter Hess
2 February 2022 | 4 min read
UBE3A expression in mouse brain slices, shown in green.

One-shot gene therapy for Angelman syndrome shows promise in mice

A potential new gene therapy delivered via a single injection mimics ratios of proteins normally found in cells.

By Charles Q. Choi
29 November 2021 | 5 min read

Explore more from The Transmitter

A disembodied hand holds a stamp over a messy stack of papers.

Exclusive: Layoffs revoked at U.S. National Institute of Neurological Disorders and Stroke

After more than a month of uncertainty, 30 previously purged employees at the institute no longer face termination.

By Angie Voyles Askham, Sydney Wyatt
21 May 2025 | 3 min read

John Beggs unpacks the critical brain hypothesis

Beggs outlines why and how brains operate at criticality, a sweet spot between order and chaos.

By Paul Middlebrooks
21 May 2025 | 94 min listen
Photograph of the BRIDGE team and students visiting a laboratory.

Sharing Africa’s brain data: Q&A with Amadi Ihunwo

These data are “virtually mandatory” to advance neuroscience, says Ihunwo, a co-investigator of the Brain Research International Data Governance & Exchange (BRIDGE) initiative, which seeks to develop a global framework for sharing, using and protecting neuroscience data.

By Lauren Schenkman
20 May 2025 | 6 min read